J. Sheppard

Publications91
h-index20
Citations1,307
Highly Influential Citations69
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • S. Pflugfelder
  • 571 Publications, 26,928 Citations
  • T. Comstock
  • 75 Publications, 2,153 Citations
  • C. S. Foster
  • 454 Publications, 13,731 Citations
  • G. Ousler
  • 157 Publications, 2,006 Citations
  • Publications
  • Influence
Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates.
PURPOSE Ocular Tracking Resistance in U.S. Today (TRUST) annually evaluates in vitro antimicrobial susceptibility of Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae to… Expand
  • 139
  • 9
Molecular and Conventional Epidemiology ofMycobacterium tuberculosis in Botswana: a Population-Based Prospective Study of 301 Pulmonary Tuberculosis Patients
ABSTRACT Little is known about patterns of tuberculosis (TB) transmission among populations in developing countries with high rates of TB and human immunodeficiency virus (HIV) infection. To examine… Expand
  • 68
  • 6
Effect of Loteprednol Etabonate 0.5% on Initiation of Dry Eye Treatment With Topical Cyclosporine 0.05%
Objective: The purpose of this work was to evaluate the effect of loteprednol etabonate (LE) before the initiation of topical cyclosporine A (tCsA) therapy in patients with mild-to-moderate dry eye… Expand
  • 39
  • 6
Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure
Corticosteroids are a mainstay therapeutic option for the treatment of ocular inflammation. However, safety remains a concern for clinicians, particularly with long-term use. Though highly effective… Expand
  • 47
  • 4
Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease.
PURPOSE This retrospective, clinical comparative analysis describes differences in clinical signs and symptoms and medication tolerability between those patients who receive topical corticosteroids… Expand
  • 58
  • 4
Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study.
PURPOSE Endogenous anterior uveitis (AU), when untreated, may lead to vision loss. This study compared the safety and efficacy of difluprednate versus prednisolone acetate for the treatment of this… Expand
  • 35
  • 4
Lacritin, a novel human tear glycoprotein, promotes sustained basal tearing and is well tolerated.
PURPOSE Lacritin is a novel human tear glycoprotein that promotes basal tear peroxidase secretion by rat lacrimal acinar cells in vitro. This study investigates whether lacritin is prosecretory when… Expand
  • 54
  • 3
  • PDF
Intracameral phenylephrine and ketorolac during cataract surgery to maintain intraoperative mydriasis and reduce postoperative ocular pain: Integrated results from 2 pivotal phase 3 studies
Purpose To evaluate the efficacy and safety of phenylephrine 1.0%–ketorolac 0.3% (Omidria) for maintenance of mydriasis during, and reduction of ocular pain after, cataract surgery. Setting Twenty… Expand
  • 20
  • 3
Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
PURPOSE To assess the efficacy and safety of lifitegrast ophthalmic solution 5.0% compared with placebo in subjects with dry eye disease. DESIGN Prospective, randomized, double-masked,… Expand
  • 108
  • 2
Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group.
PURPOSE To compare the safety and efficacy of loteprednol etabonate 0.5% ophthalmic suspension with prednisolone acetate 1.0% ophthalmic suspension in reducing the ocular signs and symptoms… Expand
  • 76
  • 2